Stroke management and the impact of mobile stroke treatment units
暂无分享,去创建一个
[1] S. Oparil,et al. Is Blood Pressure Control for Stroke Prevention the Correct Goal?: The Lost Opportunity of Preventing Hypertension , 2015, Stroke.
[2] Shyam Prabhakaran,et al. Acute stroke intervention: a systematic review. , 2015, JAMA.
[3] Eli Segal,et al. Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: a randomized clinical trial. , 2015, CJEM.
[4] M. Ebinger,et al. Improved Prehospital Triage of Patients With Stroke in a Specialized Stroke Ambulance: Results of the Pre-Hospital Acute Neurological Therapy and Optimization of Medical Care in Stroke Study , 2015, Stroke.
[5] F. Briggs,et al. Abstract T P200: Feasibility of Telemedicine on a Mobile Stroke Treatment Unit , 2015 .
[6] M. Stecker,et al. Abstract W P31: Does Portable CT Imaging in a Mobile Stroke Treatment Unit (MSTU) Provide Adequate Quality for Early Critical Decision Making? , 2015 .
[7] Andrew P. Reimer,et al. Abstract 54: Reduction in time to Imaging and intravenous Thrombolysis by in-field Evaluation and Treatment in a Mobile Stroke Treatment Unit , 2015 .
[8] M. Mittal,et al. Neighborhood socioeconomic status and stroke mortality: Disentangling individual and area effects , 2013, Neurology.
[9] Adrian F Hernandez,et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. , 2013, JAMA.
[10] W. Powers,et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.
[11] Geoff Cohen,et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis , 2012, The Lancet.
[12] Klaus Fassbender,et al. Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial , 2012, The Lancet Neurology.
[13] R. Hornung,et al. Recombinant Tissue-Type Plasminogen Activator Use for Ischemic Stroke in the United States: A Doubling of Treatment Rates Over the Course of 5 Years , 2011, Stroke.
[14] Gregory W Albers,et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.
[15] L. Goldstein,et al. Hospital Arrival Time and Intravenous t-PA Use in US Academic Medical Centers, 2001–2004 , 2009, Stroke.
[16] Mark D. Huffman,et al. Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association , 2009, Circulation.
[17] M. Kaste,et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.
[18] J. Saver. Time Is Brain—Quantified , 2006, Stroke.
[19] Scott Hamilton,et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.
[20] Joseph P. Broderick,et al. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .
[21] Michal Rozanski,et al. Effects of golden hour thrombolysis: a Prehospital Acute Neurological Treatment and Optimization of Medical Care in Stroke (PHANTOM-S) substudy. , 2015, JAMA neurology.
[22] Prevalence of stroke--United States, 2006-2010. , 2012, MMWR. Morbidity and mortality weekly report.
[23] Paul E. Schulz,et al. Why are stroke patients excluded from tPA therapy? An analysis of patient eligibility , 2001 .